Xeljanz For Psoriatic Arthritis
Xeljanz and Xeljanz XR are FDA-approved to treat active psoriatic arthritis in adults. Either drug is used for people who didnt receive enough benefit from other medications called tumor necrosis factor inhibitors. Either is also used in people who had bothersome side effects of TNF inhibitors.
With PsA, people have symptoms of arthritis and symptoms of psoriasis . This is a long-term autoimmune condition.
Xeljanz and Xeljanz XR should not be used in combination with certain other drugs for PsA.
Effectiveness for psoriatic arthritis
Tofacitinib has been found to be effective in treating PsA. Its recommended in treatment guidelines from the American College of Rheumatology. For information about how the drug performed in clinical trials, see the prescribing information.
Jak Inhibitors Have Significant Impact In Psoriatic Arthritis But Safety Concerns Remain
Disclosures: We were unable to process your request. Please try again later. If you continue to have this issue please contact .
Despite some safety concerns, Janus kinase, or JAK, inhibitors, are carving out a place as important treatment options for a number of autoimmune diseases, including psoriatic arthritis.
JAK inhibitors were first approved by the FDA for rheumatoid arthritis, with tofacitinib receiving approval in 2012, followed by baricitinib in 2018 and upadacitinib in 2019. Eventually, data from several phase 3 trials prompted the FDA to also greenlight two of these JAK inhibitors tofactinib in 2017 and upadacitnib in 2021 for treatment of PsA.
However, JAK inhibitors arrival on the market has not been without controversy, especially in light of data linking these therapies to an increased risk for cardiovascular events and cancer.
Finding their place
The FDA approval of tofacitinib, the first JAK inhibitor approved for PsA, came on the heels of the publication of two phase 3 trials OPAL Broaden and OPAL Beyond in The New England Journal of Medicine in 2017.
Notably, OPAL Broaden also included an active control arm in which patients received adalimumab . Clinical improvements were comparable in the tofacitinib and adalimumab arms, but there was no planned analysis of noninferiority or superiority of the two treatments.
Additional advantages
However, the advantages of JAK inhibitors extend beyond their efficacy, according to Wells.
Safety concerns
Xeljanz For Ulcerative Colitis
Xeljanz and Xeljanz XR are FDA-approved to treat moderately to severely active ulcerative colitis in adults. Either drug is used for people who didnt receive enough benefit from other medications called tumor necrosis factor inhibitors. Either is also used in people who had bothersome side effects from TNF inhibitors.
With UC, the lining inside of your colon or rectum is inflamed. This long-term condition can cause abdominal pain, diarrhea, and blood in your stools.
Xeljanz and Xeljanz XR should not be used in combination with certain other drugs for UC.Examples of these drugs include infliximab , azathioprine , and cyclosporine .
Effectiveness for ulcerative colitis
Tofacitinib has been found to be effective in treating UC. Its recommended in treatment guidelines from the American College of Gastroenterology. For information about how the drug performed in clinical trials, see the prescribing information.
Read Also: Does Air Conditioning Cause Arthritis
Will I Have Withdrawal Symptoms If I Stop Using Xeljanz
Possibly. If you stop taking either drug, the symptoms that you were using it to treat may come back or become worse.
A small clinical study that included people with rheumatoid arthritis found that 37% of people who stopped taking Xeljanz were able to stay off the drug for 1 year without their disease getting worse. In this study, people who had less severe RA symptoms were more likely to be able to stop taking Xeljanz without their symptoms worsening.
If youre interested in stopping Xeljanz or Xeljanz XR treatment, talk with your doctor before doing so. They can discuss with you the risks of stopping treatment.
More Common Side Effects
The more common side effects of Xeljanz and Xeljanz XR can include:
- diarrhea
Most of these side effects may go away within a few days or a couple of weeks. If theyre more severe or dont go away, talk with your doctor or pharmacist.
* For more information about this side effect, see Side effect details below.
Also Check: How To Treat Mild Arthritis In Knee
Xeljanz For Rheumatoid Arthritis
Xeljanz and Xeljanz XR are FDA-approved to treat moderately or severely active rheumatoid arthritis in adults. Either drug is used for people who didnt receive enough benefit from other medications called tumor necrosis factor inhibitors. Either is also used in people who had bothersome side effects of TNF inhibitors.
RA is an autoimmune condition that causes pain and swelling in your joints. Over time, it can cause damage to your joints.
Xeljanz and Xeljanz XR should not be used in combination with certain other drugs for RA.Examples of these drugs include infliximab , azathioprine , and cyclosporine .
Effectiveness for rheumatoid arthritis
Tofacitinib has been found to be effective in treating RA. Its recommended in treatment guidelines from the American College of Rheumatology. For information about how the drug performed in clinical trials, see the prescribing information.
Evidence For Xeljanz For Polyarticular Course Jia
Xeljanz was approved for pcJIA based on a phase 3 clinical trial. The study involved 2 phases held over 44 weeks. In total 398 people participated in the study.1
This study looked at the safety and efficacy of Xeljanz. The drug was taken as a tablet or solution based on body weight and personal preference.1
The trial showed that people with pcJIA had significantly fewer disease flares than in the placebo group. People who took XELJANZ had a 31 percent occurrence of disease flare compared to 55 percent of people who took the placebo.1
XELJANZ is already approved for:1
- Adults with moderate to severe rheumatoid arthritis after methotrexate failure
- Adults with psoriatic arthritis after DMARD failure
- Adults with moderate to severe ulcerative colitis after TNF blocker failure.
This new approval allows the prescribing of Xeljanz for a new, fourth indication: the treatment of pcJIA in children and adolescents 2 years and older.1
You May Like: How To Rule Out Rheumatoid Arthritis
Pfizer Announces Fda Approval Of Xeljanz And Xeljanz Xr For The Treatment Of Active Psoriatic Arthritis
The Food and Drug Administration has approved Xeljanz 5 mg twice daily and Xeljanz XR extended release 11 mg once daily for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs.
Xeljanz/Xeljanz XR is the first and only Janus kinase inhibitor approved by the FDA for both moderate to severe rheumatoid arthritis and active psoriatic arthritis.
Psoriatic arthritis is a complex and progressive disease with an unpredictable course, said Angela Hwang, global president, inflammation and immunology, Pfizer. The approval of Xeljanz is an important step forward for patients seeking new treatments and is a testament to Pfizers unwavering commitment to advancing patient care.
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis a condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but the joint problems can sometimes begin before skin lesions appear. Mayo Clinic
The recommended dose of Xeljanz/Xeljanz XR is in combination with nonbiologic disease-modifying antirheumatic drugs, and use in combination with biologic disease-modifying antirheumatic drugs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
Jak Inhibitors Start Working Within Three Months
How quickly JAK inhibitors take effect can vary from person to person. But if they are going to help you, youll notice results within three months, Mandelin says. There are some data out there that suggest some people can experience a meaningful difference as early as two weeks on a JAK inhibitor, he notes.
A telltale sign that theyre working? Youll notice you have fewer symptoms. Your doctor will be able to quantify this through blood testing and by asking you questions during your regular checkups.
Also Check: How To Slow Down Arthritis In Hands
Brand Selection For Medically Necessary Indications
Note: For plaque psoriasis, this policy applies to all members requesting treatment with a targeted immune modulator. For Avsola, Remicade, and Renflexis, this policy applies to all members requesting treatment with the targeted infliximab product. For all other indications, this policy applies to members who are new to treatment with a targeted immune modulator for the first time.
How Does Tofacitinib Work
Xeljanz works by decreasing a substance called cytokines. Cytokines are a protein in the body that helps control the immune system. When our bodies have an infection, cytokines increase to help fight the infection. People with RA make more cytokines than necessary, and this leads to inflammation and pain. Xeljanz disrupts cell signals in the Janus kinase pathways to reduce the production of new cytokines, according to a video on the Xeljanz website.
In people with psoriatic arthritis and ulcerative colitis, the drug works the same way to lower inflammation that causes symptoms.
In July 2019, the FDA limited the use of Xeljanz in adults with ulcerative colitis due to safety concerns. The agency had initially approved the drug for the treatment of any adult with moderately to severely active ulcerative colitis. Now the drug is only approved for adults with UC who have an inadequate response or are intolerant to another class of medications called TNF blockers.
Also Check: What Causes Arthritis In The Lower Spine
Can I Take Xeljanz With A Biologic
No, you shouldnt take Xeljanz or Xeljanz XR with a biologic drug. Biologic drugs are made in a lab from living cells. Many biologics are designed to suppress the ability of your immune system to fight infections. This is because biologics are generally used to treat autoimmune disorders, which are caused by your immune system mistakenly attacking your own body.
Taking Xeljanz or Xeljanz XR with biologics can suppress your immune system too much. This can increase your risk of very serious infections that your body wont be able to fight off.
Talk with your doctor to learn more about which medications are safe to use with Xeljanz or Xeljanz XR.
Jak Inhibitors Are Safe But Do Come With Some Risks
A study published in April 2020 in the Chinese Medical Journal found that an increased risk of infections, such as upper respiratory, was among the most common side effects of JAK inhibitors in people with psoriatic arthritis. This is because JAK inhibitors target parts of the immune system, which can lower your overall immunity.
The safety of JAK inhibitors has also made recent headlines. Results from a postmarketing study of tofacitinib delayed FDA approval of certain JAK inhibitors used for RA as treatment for psoriatic arthritis. Findings showed an increased risk of serious heart-related problems and cancer in people taking tofacitinib for RA. As a result, a black box warning was added to all JAK inhibitors, not just tofacitinib.
This is why your doctor may not prescribe a JAK inhibitor if you have cardiovascular issues or a history of blood clots. But rather than being scared by a warning, I think people with psoriatic arthritis should view this as a caution, as with any kind of , and do their due diligence, Dr. Bose adds.
Recommended Reading: Is Grapefruit Good For Arthritis
Xeljanz Receives Eu Marketing Authorisation For Juvenile Arthritis
Posted: 23 August 2021 | Anna Begley |
Xeljanz® received marketing authorisation in Europe for the treatment of juvenile idiopathic arthritis and psoriatic arthritis .
Pfizer have announced that the European Commission has approved Xeljanz® for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs .
Xeljanz is the first and only oral Janus kinase inhibitor approved in the European Union in four indications: adults with moderately to severely active rheumatoid arthritis after DMARD failure or intolerance adults with active PsA after DMARD failure or intolerance adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent and active polyarticular JIA and juvenile PsA in patients two years of age and older who have responded inadequately to previous therapy with DMARDs.
The polyarticular JIA and juvenile PsA approval is based on data from a Phase III pivotal study in patients with polyarticular JIA as well as other JIA subtypes. The study had two phases: an 18-week open-label, run-in phase, followed by a 26-week double-blind, placebo-controlled, randomised, withdrawal phase for a total duration of 44 weeks.
Why Is This An Important Approval For People With Juvenile Idiopathic Arthritis
Children with pcJIA are more challenging to treat because of the involvement of many joints. Children with pcJIA do not always respond to treatment and therefore are at increased risk for joint damage.
This results in worse outcomes and decreased quality of life. Although more treatments are becoming available, there is still a lot that is unknown about pcJIA.2
Read Also: Does Psoriatic Arthritis Affect Eyes
Drug Forms And Administration
Xeljanz contains the drug tofacitinib. It comes as a tablet thats taken by mouth, once or twice a day. It also comes as an oral solution thats taken twice daily.
Humira contains the drug adalimumab. Its given as a subcutaneous injection, typically once every other week. Your healthcare professional may give you the injection, or they may show you how to self-inject Humira at home.
Eu Approves Pfizers Xeljanz For Psoriatic Arthritis
The European Commission has approved Pfizers Xeljanz as a treatment for psoriatic arthritis , significantly expanding the drugs scope.
European regulators are allowing use of Xeljanz 5mg twice daily in combination with methotrexate for to treat active PsA in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug therapy.
The decision gives patients the opportunity to access a new treatment approach, as the drug is the first and only oral Janus kinase inhibitor to be approved in EU for the condition, which affects between 1.5 and 3 million people in the region.
Approval came on the back of data from the Phase III Oral Psoriatic Arthritis TriaLs clinical development programme, which demonstrated statistically significant improvements in American College of Rheumatology 20 response and change from baseline in the Health Assessment QuestionnaireDisability Index score.
In OPAL Broaden, 50 percent of patients taking Xeljanz 5mg twice daily achieved an ACR20 response compared to 33 percent of patients in the placebo arm, while in OPAL Beyond, 50 percent of patients achieved an ACR20 response with Xeljanz 5mg twice daily compared to 24 percent of those given a placebo.
Pfizer also noted that in both studies, statistically significant improvements in ACR20 response were recorded in the treatment arm versus placebo at week two, thereby meeting a secondary endpoint.
Don’t Miss: How To Tell If You Have Rheumatoid Arthritis
The Approval Makes Xeljanz The First Jak Inhibitor Approved To Treat Ankylosing Spondylitis And Rinvoq The Second Approved For Psoriatic Arthritis
As of this week, people with ankylosing spondylitis or psoriatic arthritis have some new options for treating their condition.
On December 14, the U.S. Food & Drug Administration approved tofacitinib for the treatment of AS, making it the first Janus kinase inhibitor that can officially be used for AS. On the same date, the agency also approved upadactinib for the treatment of PsA.
Tofacitinib was initially approved for rheumatoid arthritis . Since then, it has also gained approval for PsA, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.
Upadactinib was previously approved for the treatment of RA.
The FDA approved tofacitinib for AS after reviewing a phase 3, double-blinded study. The study found that about 40 percent of AS patients who took tofacitinib had a 40 percent improvement in disease activity scores compared to a 12.5 percent improvement in AS patients who got a placebo.
The FDA approved upadactinib for PsA after evaluating two phase 3 studies. In one, more than 70 percent of PsA patients who used upadactinib had significant improvement in disease activity scores compared to 36 percent of those who used a placebo. In the second study, 57 percent of the upadactinib group improved significantly versus 24 percent of those who got a placebo.
All three of these drugs come with the caveat from the FDA that patients should only use them if they have not responded well enough to a tumor necrosis factor biologic .
Xeljanz And Xeljanz Xr
Xeljanz is available in these forms:
- Xeljanz , which is released at once in your body after its taken. It comes as:
- 5-milligram and 10-mg oral tablets
- 1 mg/milliliter oral solution
Don’t Miss: How To Relieve Arthritis Pain In Knuckles
Moderate To Severe Plaque Psoriasis
As defined in Aetna commercial policies, health care services are not medically necessary when they are more costly than alternative services that are at least as likely to produce equivalent therapeutic or diagnostic results. Avsola , Cimzia , Cosentyx , Enbrel , Remicade , Renflexis , and Siliq are more costly to Aetna than other targeted immune modulators for moderate to severe plaque psoriasis. There is a lack of reliable evidence that Avsola , Cimzia , Cosentyx , Enbrel , Remicade , Renflexis , and Siliq are superior to the lower cost targeted immune modulators: Humira, Ilumya, Inflectra, Otezla, Skyrizi, Stelara, Taltz, and Tremfya for moderate to severe plaque psoriasis. Therefore, Aetna considers Avsola , Cimzia , Cosentyx , Enbrel , Remicade , Renflexis , and Siliq to be medically necessary only for members who have a contraindication, intolerance or ineffective response to the available equivalent alternative targeted immune modulators: Humira, Ilumya, Inflectra, Otezla, Skyrizi, Stelara, Taltz, and Tremfya per criteria below. Requirements for a trial of lower cost targeted immune modulators are waived for persons requesting Cimzia who are pregnant or breastfeeding.